Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subasumstat mass balance and pharmacokinetics in advanced solid tumors
NCT05976334Phase 1Terminated
- Sponsor
- Takeda
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of subasumstat in solid tumor (2 arms), sponsored by Takeda. Primary endpoints: Cumulative Percentage of Urinary Recovery at 14 days, Cumulative Percentage of Fecal Recovery at 14 days and 3 more. Started Nov 2023; status: terminated.
02
Drugs
subasumstat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05976334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976334.